Stealth’s Elamipretide Granted FDA Orphan Drug Status for Primary Mitochondrial Myopathy

Stealth’s Elamipretide Granted FDA Orphan Drug Status for Primary Mitochondrial Myopathy | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

Stealth’s Elamipretide Granted FDA Orphan Drug Status for Primary Mitochondrial Myopathy

Elamipretide is a peptide that specifically targets mitochondria. It reduces the number of free radicals and penetrates the cellular and outer ...